GlassScriptPhysician profile
Diana Dickson-Witmer
NPI 1932189131
$798.39
in general payments reported to CMS, 2019-2025
14 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.87 · 2021: $37.81 · 2023: $223 · 2024: $235 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Molli Surgical (US) INC | $160.92 | 2023 | |
| Stemline Therapeutics INC. | $123.46 | 2025 | Orserdu |
| Baxter Healthcare | $92.20 | 2024 | Tisseel |
| Lilly USA, LLC | $91.89 | 2024 | |
| Bioptics, INC. | $71.87 | 2019 | |
| Daiichi Sankyo INC. | $46.56 | 2024-2025 | Enhertu, Injectafer |
| Myriad Genetic Laboratories, INC. | $38.96 | 2023-2025 | Myrisk |
| Ethicon US, LLC | $33.85 | 2024 | Vistaseal |
| Merck Sharp & Dohme LLC | $31.75 | 2023 | Keytruda, Lynparza |
| Menarini Silicon Biosystems, INC. | $28.35 | 2025 | Cellsearch |
| Novartis Pharmaceuticals Corporation | $27.00 | 2025 | |
| Genzyme Corporation | $24.74 | 2021 | |
| Morphosys, US INC. | $13.77 | 2023 | Monjuvi |
| Pacira Pharmaceuticals Incorporated | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Dickson-Witmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.